CN Patent

CN115023240B — 抗癌剂组合物

Assigned to Carna Biosciences Inc · Expires 2024-08-23 · 2y expired

What this patent protects

本发明提供组合了可逆BTK抑制剂与BCL‑2抑制剂的治疗癌症的新方法。具体地，提供组合了以下的BTK抑制剂与维奈托克的抗癌剂组合物。

USPTO Abstract

本发明提供组合了可逆BTK抑制剂与BCL‑2抑制剂的治疗癌症的新方法。具体地，提供组合了以下的BTK抑制剂与维奈托克的抗癌剂组合物。

Drugs covered by this patent

chembl-chembl1946170 (REGORAFENIB)

Patent Metadata

Patent number: CN115023240B
Jurisdiction: CN
Classification: —
Expires: 2024-08-23
Drug substance claim: No
Drug product claim: No
Assignee: Carna Biosciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.